SPRO

Spero Therapeutics Inc.

Price

$1.21

return (12m)

-39.50%

p/e

9.50

p/bv

1.59

DIVIDEND YIELD

0.00%

SPRO price

Spero Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment SPRO

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

1.26%

3 months

-57.24%

1 year

-39.50%

2 years

-11.68%

5 years

-92.87%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals SPRO

Valuation

P/E

9.50

Sector -4.26

Industry -4.26

P/BV

1.59

Sector 2.11

Industry 2.11

P/Revenue (PSR)

1.49

Sector 2.08

Industry 2.08

EV/EBITDA

Sector -546.19

Industry -546.19

EV/EBIT

Sector -37.31

Industry -37.31

P/EBITDA

Sector -50.76

Industry -50.76

P/EBIT

Sector -39.62

Industry -39.62

P/Total Assets

1.33

Sector 1.25

Industry 1.25

P/Net Current Assets

1.63

Sector -5.47

Industry -5.47

P/Working Capital

1.63

Sector -1.10

Industry -1.10

EPS

0.13

Sector -1.94

Industry -1.94

BVPS

0.76

Sector 1.89

Industry 1.89

Efficiency

Gross Margin

100.00%

Sector 38.90%

Industry 38.90%

EBITDA Margin

Sector -13,872.56%

Industry -13,872.56%

EBIT Margin

Sector -4,253,834.43%

Industry -4,253,834.43%

Operating Margin

12.81%

Sector -36.74%

Industry -36.74%

Net Profit Margins

15.72%

Sector -37.51%

Industry -37.51%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

16.72%

Sector -61.50%

Industry -61.50%

ROA

14.00%

Sector -63.85%

Industry -63.85%

ROIC

0.00%

Sector -498.30%

Industry -498.30%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

6.12

Sector 2.89

Industry 2.89

Net Debt / EBITDA

Sector -39,048,222.71

Industry -39,048,222.71

Net Debt / EBIT

Sector -10.24

Industry -10.24

Net Debt / Equity

0.00

Sector -0.60

Industry -0.60

Gross Debt / Equity

0.00

Sector -0.83

Industry -0.83

Equity/Assets

0.84

Sector 0.43

Industry 0.43

Liabilities/Assets

0.16

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

20.83%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF Spero Therapeutics ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$1.21

Fair Value

$1.49

Upside Return potential.

23.22%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals SPRO

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
SPRO Spero Therapeutics Inc.	$1.21	-34.59%	0.00%	9.50	1.59	16.72%	15.72%
JNJ Johnson & Johnson	$266.50	55.29%	1.93%	31.09	7.70	24.76%	21.48%
PFE Pfizer Inc.	$27.87	21.03%	6.26%	35.86	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$256.91	27.42%	2.58%	74.16	-78.93	-106.44%	9.81%
NVO Novo Nordisk A/S	$45.62	-14.65%	3.95%	11.47	6.09	53.11%	35.32%
MRK Merck & Co. Inc.	$147.77	82.61%	2.24%	116.78	8.81	7.55%	4.76%
AZN AstraZeneca PLC	$161.98	3.71%	1.93%	24.59	5.10	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$66.29	45.78%	3.73%	14.81	6.16	41.55%	18.85%
ZTS Zoetis Inc.	$76.84	-49.43%	2.67%	12.20	10.25	84.02%	27.77%
REGN Regeneron Pharmaceuticals Inc.	$792.43	37.47%	0.44%	19.71	2.69	13.65%	27.86%
AMGN Amgen Inc.	$432.42	55.55%	2.22%	27.25	20.39	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$105.00	43.48%	0.00%	30.73	88.55	288.14%	24.86%
MCK McKesson Corporation	$897.16	31.93%	0.38%	19.60	-26.88	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$542.40	39.41%	0.00%	31.57	6.87	21.76%	35.00%
CAH Cardinal Health Inc.	$235.19	59.60%	0.88%	35.20	-20.39	-57.93%	0.62%
HRMY Harmony Biosciences Holdings Inc.	$39.29	3.26%	0.00%	12.32	2.23	18.14%	18.89%
BIIB Biogen Inc.	$217.24	59.31%	0.00%	38.68	1.71	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

SPRO Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Spero Therapeutics

Spero Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

13 years

Founded: 2013

2017

Time since IPO - 9 years

89

Employees

Spero Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $70.18 million, with shareholders equity totaling $44.20 million.

The company employs approximately 89 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Spero Therapeutics Inc. reported $47.00 million in revenue, generating net income of $7.39 million.

Key financial metrics include a P/E ratio of 9.50, a price-to-book (P/B) ratio of 1.59, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker SPRO.

Market cap

$70.18 million

Net worth

$44.20 million

$44,200,000.00

Assets

$52.77 million

$52,770,000.00

Total Shares Outstanding

58.00 million

58,000,000

Average Daily Trading Volume

$1.74 million

$1,742,403.42

Sector

Health Care

Industry

Biotechnology

SPRO

SPRO revenue and profits

Financial Results SPRO

DRAG THE FRAME TO SEE MORE DATA

SPRO cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$897.16 31,33% (12M)

P/E

19.60

0.38%

ROE

-137.16%

P/BV

-26.88

CAH - Cardinal Health

$235.19 60,10% (12M)

P/E

35.20

0.88%

ROE

-57.93%

P/BV

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12M)

P/E

31.09

1.93%

ROE

24.76%

P/BV

7.70

ABBV - AbbVie

$256.91 26,00% (12M)

P/E

74.16

2.58%

ROE

-106.44%

P/BV

-78.93

MRK - Merck & Co.

$147.77 82,50% (12M)

P/E

116.78

2.24%

ROE

7.55%

P/BV

8.81

AZN - AstraZeneca

$161.98 3,46% (12M)

P/E

24.59

1.93%

ROE

20.74%

P/BV

5.10

PFE - Pfizer

$27.87 22,54% (12M)

P/E

35.86

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$897.16 31,33% (12 M)

P/L

19.60

0.38%

ROE

-137.16%

P/VP

-26.88

CAH - Cardinal Health

$235.19 60,10% (12 M)

P/L

35.20

0.88%

ROE

-57.93%

P/VP

-20.39

JNJ - Johnson & Johnson

$266.50 54,96% (12 M)

P/L

31.09

1.93%

ROE

24.76%

P/VP

7.70

ABBV - AbbVie

$256.91 26,00% (12 M)

P/L

74.16

2.58%

ROE

-106.44%

P/VP

-78.93

MRK - Merck & Co.

$147.77 82,50% (12 M)

P/L

116.78

2.24%

ROE

7.55%

P/VP

8.81

AZN - AstraZeneca

$161.98 3,46% (12 M)

P/L

24.59

1.93%

ROE

20.74%

P/VP

5.10

PFE - Pfizer

$27.87 22,54% (12 M)

P/L

35.86

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Spero Therapeutics (SPRO) today?

A cotação de Spero Therapeutics (SPRO) hoje está em US$ 1.21, com uma variação de -39.5% em relação ao último ano. A cotação de Spero Therapeutics (SPRO) iniciou o ano negociando na casa dos US$ 2.33 e hoje está em US$ 1.21. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Spero Therapeutics (SPRO) e dados de ações do Ibovespa e mercados internacionais.

Quando Spero Therapeutics (SPRO) paga dividendos?

Spero Therapeutics (SPRO) não distribuiu dividendos no último ano.

Is Spero Therapeutics (SPRO) a good investment?

Atualmente, Spero Therapeutics (SPRO) está cotada a US$ 1.21, com um P/L de 9.50, representando um desvio de 503% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de -39.5 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de -39.50%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Spero Therapeutics (SPRO) stock?

Investir em ações de Spero Therapeutics (SPRO) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Spero Therapeutics (SPRO) yield today?

A rentabilidade de Spero Therapeutics (SPRO) foi de 1.26% no último mês, -39.50% no último ano e -92.87% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Spero Therapeutics (SPRO) hoje, o investimento total seria de US$ 121.00, com base na cotação atual de US$ 1.21.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 73.21
Em 5 anos: US$ 8.63
Em 10 anos: US$ 121.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

SPRO

Spero Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment SPRO

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING SPRO WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Spero Therapeutics

Spero Therapeutics Inc.

United States

13 years

2017

89

PROFIT X PRICE SPRO

Financial Results SPRO

SPRO cash flow

Asset, Revenue and Profit Growth - SPRO

SPRO balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions